Artiva Biotherapeutics Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors.

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m.

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress. “Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D.

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment

In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Pearl Diver Credit Co LLC

24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.

Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares

Artiva Biotherapeutics, Inc. debuts on NASDAQ with a $167 million IPO, expected to close on July 22, 2024. AlloNK therapy aims to enhance efficacy of B-cell depleting monoclonal antibodies for autoimmune disorders and cancers. Initial data from either investigator trial or phase 1/1b study using AlloNK + rituximab combination for treatment of patients with SLE/LN/autoimmune disorders, expected in the 1st half of 2025.

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Actuate Therapeutics Inc

Ardent Health Partners LLC

Bloomz Inc

Concentra Group Holdings Parent Inc

Lineage Inc

Latam Airlines Group SA

Onestream Inc

QMMM Holdings Ltd

TWFG Inc

Viking Holdings Ltd

A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in the week ahead and are set to raise a combined $5.1 billion, the most for any week so far this year. One SPAC is also set to debut.

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the pricing of its upsized initial public offering of 13,920,000 shares of common stock at a price to the public of $12.00 per share. All of the shares of common stock are being offered by Artiva.

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

News for Artiva Biotherapeutics Inc Stock (ARTV)